Aptamer Group plc (LSE:APTA) has agreed a cost-sharing scientific collaboration with miRNA specialist Pharmahungary Group. The company says the deal gives it access to an in vivo data package that would typically cost £300,000 to £500,000, and lets it keep full ownership of its Optimer delivery vehicles.

What was announced

On Monday 26 October 2026, York-based Aptamer Group plc (LSE:APTA) announced a scientific collaboration with Pharmahungary Group, a biotech company developing microRNA (miRNA) therapeutics. The release was headlined "Optimer® collaboration targets heart and skeletal muscle". The aim is to generate preclinical data supporting future partnering of Optimer targeted delivery to heart and skeletal muscle.

Under the agreement, Aptamer will develop two Optimer delivery vehicles, one directed at heart muscle cells and one at skeletal muscle. It will fund development and validation of the targeting system and manufacture Optimer conjugates carrying Pharmahungary's miRNA. Pharmahungary will fund the preclinical studies, including in vitro assays and in vivo studies in disease-relevant animal models, to assess targeting, preliminary safety and efficacy.

The terms

The collaboration is cost-sharing: each party funds its own work and keeps its own intellectual property. Aptamer said a comparable preclinical package would typically cost £300,000 to £500,000. It added that the deal requires no unbudgeted spending and does not change its cash runway projections. In return for its work, Aptamer gains access to a package of in vivo animal study data.

Aptamer keeps full ownership of its Optimer delivery vehicles and related IP. It will own 50% of the combined Optimer-miRNA therapeutic developed under the collaboration. If the work succeeds, the two companies intend to jointly pursue licensing deals with pharmaceutical partners. No upfront payments, milestones or royalty terms are disclosed, and no timetable for the studies is given.

Chief executive Dr Arron Tolley said: "Pharmahungary Group is a leading authority in cardiac miRNA, and we are delighted that it has chosen Optimer® technology." He described the deal as excellent progress against the goals set after the company's fundraising, and a capital-efficient way to generate partner-ready preclinical data while keeping full ownership of the Optimer vehicle.

Professor Péter Ferdinandy, founder and chief executive of Pharmahungary Group, said: "We have over two decades of experience developing cardioprotective miRNAs and the preclinical models needed to test them." He said delivering miRNA therapeutics into heart and skeletal muscle cells is a key challenge for the field, and added: "Our goal is to generate the in vivo evidence needed to take this combined approach to pharmaceutical partners."

Why muscle delivery matters

Aptamer noted that approved oligonucleotide drugs act mainly in the liver, and that no targeted delivery system for cardiac or skeletal muscle cells has yet been approved. Potential uses it lists include ischaemic heart disease, which it describes as a leading global cause of death, acute myocardial infarction, heart failure and muscle disorders such as sarcopenia. The company cited a Markets and Markets forecast that the oligonucleotide therapeutics market will reach US$17.7 billion by 2030. That figure is a third-party market forecast, not a projection of Aptamer's own revenue.

Founded in 2008, Aptamer develops Optimer binders, which it describes as next-generation synthetic alternatives to antibodies. It runs a dual-revenue model, combining near-term fee-for-service discovery work with a proprietary pipeline aimed at licensing, royalties and supply agreements. Other pipeline programmes include targeted delivery to fibrotic tissue, the kidney and across the blood-brain barrier, plus radioligand therapy work.

What to watch next

The key next step is the preclinical data. Investors will look for in vitro and animal results showing that the two Optimer vehicles reach heart and skeletal muscle cells and deliver their miRNA payload safely. Any licensing talks with pharmaceutical companies would depend on those results. Dr Tolley said he looks forward to updating shareholders as the work progresses. The announcement does not give a date for first data.